Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hepatitis C virus internal ribosome entry site (HCV IRES) is a highly structured RNA element located within the 5′ untranslated region (5′ UTR) of the HCV genome. It enables cap-independent translation initiation, allowing the viral RNA to directly recruit host ribosomes and initiate protein synthesis without relying on the typical 5′ cap structure used by most eukaryotic mRNAs. It directly binds both ribosomal proteins and rRNA via specific sequence/structural motifs.
Direct binding of the 40S ribosomal subunit, positioning it at or near the start codon for translation initiation, bypassing cap-dependent translation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis C Virus RNA Internal Ribosome Entry Site (HCV IRES).